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associated with adverse events. Patient data can also be
monitored to evaluate financial and clinical outcomes.
MDRA 2000 can serve as a warning system to alert clini-
cians to patients at risk for disease and can assist in the
selecting appropriate strategies for patient management.
The workshop will entail a demonstration of this soft-
ware tool along with an example of risk assessment strat-
egies for a specific disease.
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WORKSHOP OBJECTIVE: The prospective collection
of real-world data on schizophrenia care allows for the
analysis of a broad range of clinical, functional, quality
of life, and economic outcomes. This workshop will: 1)
explore the development of a comprehensive research in-
frastructure for coordination and evaluation of such
data, 2) present the results of analyses conducted on par-
ticipant baseline and physician survey data, and 3) dis-
cuss the use of methodologies for the coordination and
analysis of complex treatment patterns in schizophrenia.
PARTICIPANTS WHO WOULD BENEFIT: Profession-
als who are or expect to be involved in prospective out-
come studies and others interested in the application of
outcomes analyses derived from real-world treatment ex-
periences.
Data on SCAP participants are collected from clinical as-
sessment, self-report, medical records, and administrative
records at 6-month intervals over 3 years. Participants
are being enrolled through six major sites of service deliv-
ery across the United States. The total sample will be
2400 participants. Issues relating to the development of a
coordinated research database and the coordination of
research efforts will be discussed in section one of this
workshop. In section two, the results of baseline analyses
(n  562) conducted on the sample characteristics, on se-
lected clinical, functional, and quality of life outcomes,
and on the impact of those outcomes on service utiliza-
tion will be presented. The factors that facilitate or limit
the adoption and diffusion of new atypical antipsychotics
among physicians treating the SCAP participants (n 
240) will also be discussed. In the final section, a taxo-
nomic approach to the analysis of medication utilization
patterns is discussed within the framework of current
practice, physician behavior, and standards of practice
for the treatment of schizophrenia. Attendees will gain an
understanding of the issues concomitant with collecting,
assessing, and applying the results of prospective data de-
rived from real-world treatment settings.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop and enhance skills for designing and
conducting pharmacoeconomic analyses of diagnostic
screening and testing (DST). The workshop will focus on
three issues: 1) the nature of the available data on the test
parameters (e.g., sensitivity, specificity), 2) differential
time horizons of the DST alternatives, and 3) the non-
independence of sequential tests.
PARTICIPANTS WHO WOULD BENEFIT: Researchers
in academia and industry who employ pharmacoeconom-
ics to evaluate DST technologies, as well as decision-
makers who must approve these technologies for reim-
bursement.
Pharmacoeconomic analyses of DST technologies can be
more complex than those of medical treatments. Often
the most straightforward decision tree requires probabili-
ties (e.g., the positive and negative predictive values) that
must be calculated from the available test parameters.
What is the correct decision tree structure given available
information? Is Bayesian revision or “tree-flipping” re-
quired? Additionally, analysts may encounter difficulties
when comparing DST alternatives with differential time
horizons. What needs to be considered when comparing
an expensive test that will result in much earlier treat-
ment to a less costly test that takes longer to complete?
Lastly, combinations of sequential tests may be com-
pared to a single test. Given that the individual test re-
sults are no longer independent of each other, how
should the specificity and sensitivity of the individual
tests be modified to account for this? We will employ two
examples to illustrate these issues and demonstrate how
to: 1) identify these problems, 2) appropriately address
them, and 3) present the methods and results to the end-
user of the analysis.
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WORKSHOP OBJECTIVE: This workshop will provide
a brief overview of the field of women’s health research
and ways in which gender-based biology can be incorpo-
rated into general outcomes research, particularly for
clinical trials.
